Trial reportEuropean heart journal2024
Optical coherence tomography predictors of clinical outcomes after stent implantation: the ILUMIEN IV trial.
Trial report in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials.Nature reviews. Cardiology · 2026Review
- Digital stent enhancement for coronary stent optimization during PCI: evidence, applications, and future directions.Cardiovascular intervention and therapeutics · 2026Review
- Stent Undersizing and Malapposition: Mechanical Causes of Acute and Late Stent Failure.Reviews in cardiovascular medicine · 2026Review
- OCT-Guided PCI According to Lesion Length and Vessel Diameter: Post Hoc Analysis of OCCUPI Trial.JACC. Asia · 2026Article
- Clinical Impact and Lesion Characteristics of Suboptimal Optical Coherence Tomography Stent Deployment in Patients With Acute Myocardial Infarction.Journal of the American Heart Association · 2026Article
- Intravascular Imaging for Facilitated Coronary Interventions in DES Era.Journal of cardiovascular development and disease · 2026Review
- Synergistic fusion of CD47, VE-cadherin and mussel adhesion protein promotes endothelialization and suppresses inflammation in vascular stents.Bioactive materials · 2026Article
- Intravascular Imaging-Guided Percutaneous Coronary Intervention: Transforming Precision and Outcomes in Contemporary Practice.Journal of clinical medicine · 2025Article
- The importance of post-dilatation during PCI: current evidence and future directions.Future cardiology · 2025Article
- Optical Coherence Tomography in Acute Coronary Syndromes.Reviews in cardiovascular medicine · 2025Review
- Associations of Thrombotic and Bleeding Risks With Plaque Morphology.Circulation reports · 2025Article
- Association between post-PCI vessel fractional flow reserve (vFFR) and optical coherence tomography (OCT) findings: Results from the FAST OCT study.International journal of cardiology. Heart & vasculature · 2025Article
- Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Diagnostics (Basel, Switzerland) · 2025Review
- Intracoronary Optical Coherence Tomography: Technological Innovations and Clinical Implications in Cardiology.Current treatment options in cardiovascular medicine · 2025Review
- All-comEr Registry of OCT (AERO) to Investigate the MLD-MAX Algorithm for OCT-guided-precision-PCI in Daily Routine: Rationale and Study Design of ILUMIEN-V-AERO.Interventional cardiology (London, England) · 2025Article
- Optical theranostics in ischemic heart disease: from molecular insights to clinical translation.Theranostics · 2025Review
- Intravascular imaging-guided drug-coated balloon treatment for coronary artery disease:Evidence and practice.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
BACKGROUND AND
aimsObservational registries have suggested that optical coherence tomography (OCT) imaging-derived parameters may predict adverse events after drug-eluting stent (DES) implantation. The present analysis sought to determine the OCT predictors of clinical outcomes from the large-scale ILUMIEN IV trial.
methodsILUMIEN IV was a prospective, single-blind trial of 2487 patients with diabetes or high-risk lesions randomized to OCT-guided versus angiography-guided DES implantation. All patients underwent final OCT imaging (blinded in the angiography-guided arm). From more than 20 candidates, the independent OCT predictors of 2-year target lesion failure (TLF; the primary endpoint), cardiac death or target-vessel myocardial infarction (TV-MI), ischaemia-driven target lesion revascularization (ID-TLR), and stent thrombosis were analysed by multivariable Cox proportional hazard regression in single treated lesions.
resultsA total of 2128 patients had a single treated lesion with core laboratory-analysed final OCT. The 2-year Kaplan-Meier rates of TLF, cardiac death or TV-MI, ID-TLR, and stent thrombosis were 6.3% (n = 130), 3.3% (n = 68), 4.3% (n = 87), and 0.9% (n = 18), respectively. The independent predictors of 2-year TLF were a smaller minimal stent area (per 1 mm2 increase: hazard ratio 0.76, 95% confidence interval 0.68-0.89, P < .0001) and proximal edge dissection (hazard ratio 1.77, 95% confidence interval 1.20-2.62, P = .004). The independent predictors of cardiac death or TV-MI were smaller minimal stent area and longer stent length; of ID-TLR were smaller intra-stent flow area and proximal edge dissection; and of stent thrombosis was smaller minimal stent expansion.
conclusionsIn the ILUMIEN IV trial, the most important OCT-derived post-DES predictors of both safety and effectiveness outcomes were parameters related to stent area, expansion and flow, proximal edge dissection, and stent length.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.